Dr. Navari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
832 Princeton Ave
Birmingham, AL 35211Phone+1 205-397-8934Fax+1 205-206-8300
Summary
- Dr. Rudolph Navari is an oncologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including St. Vincent Kokomo, Saint Joseph Health System, University of Alabama Hospital, and University of Alabama Hospital. He received his medical degree from Virginia Commonwealth University School of Medicine and has been in practice 40 years. He specializes in hematologic oncology.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1981 - 1983
University of Alabama Medical CenterResidency, Internal Medicine, 1977 - 1980
Virginia Commonwealth University School of MedicineClass of 1977
Certifications & Licensure
FL State Medical License 2023 - Present
IN State Medical License 1998 - 2025
MO State Medical License 2020 - 2025
MS State Medical License 2016 - 2025
OR State Medical License 2023 - 2025
AL State Medical License 1978 - 2024
IL State Medical License 1998 - 1999- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy Start of enrollment: 2014 Aug 01
- Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients Start of enrollment: 2017 Jul 12
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy Start of enrollment: 2018 Oct 15
- Join now to see all
Publications & Presentations
PubMed
- 4 citations2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough naus...Bernardo Leon Rapoport, Jørn Herrstedt, Rebecca Clark Snow, Venkatraman Radhakrishnan, Mitsue Saito
Supportive Care in Cancer. 2023-12-18 - 1 citationsWork loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.Lee Schwartzberg, Rudolph M Navari, Kathryn J Ruddy, Thomas W LeBlanc, Rebecca Clark-Snow
Supportive Care in Cancer. 2023-10-25 - Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Rand...Rudolph M Navari, Jennifer Le-Rademacher, Fabrice Smieliauskas, Kathryn J Ruddy, Thomas James Saphner
The Oncologist. 2023-08-03
Journal Articles
- The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting—ReplyCharles L Loprinzi, Rudolph M Navari, JAMA Oncology
- Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingRudolph M Navari, Costantine Albany, Charles L Loprinzi, JAMA Oncology
Authored Content
- Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020
- Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020
Press Mentions
Helsinn Publishes Results from a Secondary Analysis of a Phase 3 Trial in Patients with CINV Helsinn Publishes Results from a Secondary Analysis of a Phase 3 Trial in Patients with CINVJanuary 4th, 2023
FDA Updates Highlighting the Latest Cancer TreatmentsNovember 20th, 2019
Study Finds Guideline Adoption Slow for Antiemetic Prophylaxis in Patients Receiving CarboplatinNovember 2nd, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
